Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 617-622

  Goudis, Christos A ^a   Korantzopoulos, Panagiotis ^b   Ntalas, Ioannis V ^b   Kallergis, Eleftherios M ^c   Liu, Tong ^d   Ketikoglou, Dimitrios G ^e  

^a General Hospital of Grevena   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d Second Hosp of Tianjing Med Univ   (China)

^e INTERBALKAN MEDICAL CENTER   (Greece)

Author keywords

Atrial fibrillation; Atrial remodeling; Diabetes mellitus; Upstream therapies

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CANDESARTAN; GAP JUNCTION PROTEIN; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; XANTHINE OXIDASE INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIOXIDANT;

ABLATION THERAPY; ACTION POTENTIAL DURATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATRIAL FIBRILLATION; AUTONOMIC DYSFUNCTION; CATHETER ABLATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DRUG TARGETING; EXCITATION CONTRACTION COUPLING; GLYCEMIC CONTROL; HEART ATRIUM REMODELING; HEART MUSCLE REFRACTORY PERIOD; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; ANIMAL; HEART VENTRICLE REMODELING; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; DIABETES MELLITUS; HUMANS; OXIDATIVE STRESS; RISK FACTORS; VENTRICULAR REMODELING;

EID: 84929899795     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.052     Document Type: Review

References (92)

1. J. Ball, M.J. Carrington, J.J. McMurray, S. Stewart, Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century, Int. J. Cardiol. 167 (2013) 1807-1824.
2. F. Rahman, G.F. Kwan, E.J. Benjamin, Global epidemiology of atrial fibrillation, Nat. Rev. Cardiol. 11 (2014) 639-654.
3. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, P.A. Wolf, Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study, JAMA 271 (1994) 840-844.
4. R.R. Huxley, K.B. Filion, S. Konety, A. Alonso, Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation, Am. J. Cardiol. 108 (2011) 56-62.
5. X. Du, T. Ninomiya, B. de Galan, E. Abadir, J. Chalmers, A. Pillai, et al., ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study, Eur. Heart J. 30 (2009) 1128-1135.
6. M.R. Movahed, M. Hashemzadeh, M.M. Jamal, Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease, Int. J. Cardiol. 105 (2005) 315-318.
7. R. Pfister, G. Michels, R. Cairns, C.A. Schneider, E. Erdmann, Incidence of new onset bundle branch block and atrial fibrillation in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study, Int. J. Cardiol. 153 (2011) 233-234.
8. T.A. Aksnes, R.E. Schmieder, S.E. Kjeldsen, S. Ghani, T.A. Hua, S. Julius, Impact of newonset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial), Am. J. Cardiol. 101 (2008) 634-638.
9. C.J. Ostgren, J. Merlo, L. Råstam, U. Lindblad, Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community, Diabetes Obes. Metab. 6 (2004) 367-374.
10. R.R. Huxley, A. Alonso, F.L. Lopez, K.B. Filion, S.K. Agarwal, L.R. Loehr, et al., Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study, Heart 98 (2012) 133-138.
11. Y. Iguchi, K. Kimura, K. Shibazaki, J. Aoki, K. Sakai, Y. Sakamoto, et al., HbA1c and atrial fibrillation: a cross-sectional study in Japan, Int. J. Cardiol. 156 (2012) 156-159.
12. G.A. Nichols, K. Reinier, S.S. Chugh, Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation, Diabetes Care 32 (2009) 1851-1856.
13. N. Dagres, R. Nieuwlaat, P.E. Vardas, D. Andresen, S. Lévy, S. Cobbe, D.T. Kremastinos, G. Breithardt, D.V. Cokkinos, H.J. Crijns, Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation, J. Am. Coll. Cardiol. 49 (2007) 572-577.
14. A.M. Salam, H.A. AlBinali, A.W. Al-Mulla, N. Asaad, R. Singh, A. Al-Qahtani, J. Al Suwaidi, Women hospitalized with atrial fibrillation: gender differences, trends and outcome from a 20-year registry in a Middle Eastern country (1991-2010), Int. J. Cardiol. 168 (2013) 975-980.
15. T. Schoen, A.D. Pradhan, C.M. Albert, D. Conen, Type 2 diabetes mellitus and risk of incident atrial fibrillation in women, J. Am. Coll. Cardiol. 60 (2012) 1421-1428.
16. G. Targher, A. Mantovani, I. Pichiri, R. Rigolon, M. Dauriz, G. Zoppini, et al., Nonalcoholic fatty liver disease is associatedwith an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes, Clin. Sci. (Lond.) 125 (2013) 301-309.
17. D.J. Campbell, J.B. Somaratne, A.J. Jenkins, D.L. Prior, M. Yii, J.F. Kenny, A.E. Newcomb, C.G. Schalkwijk, M.J. Black, D.J. Kelly, Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels, PLoS One 7 (2012) e49813.
18. R.R. Huxley, F.L. Lopez, A.R. Folsom, S.K. Agarwal, L.R. Loehr, E.Z. Soliman, R. Maclehose, S. Konety, A. Alonso, Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study, Circulation 123 (2011) 1501-1508.
19. L. Lipworth, H. Okafor, M.T. Mumma, T.L. Edwards, D.M. Roden, W.J. Blot, D. Darbar, Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study, Am. J. Cardiol. 110 (2012) 1637-1642.
20. Q. Shen, D. Cordato, D.K. Chan, J. Ip, J. Ng, Risk factor profile in Chinese-Australian stroke patients living in Sydney, Australas. J. Ageing 30 (2011) 143-147.
21. A.M. Salam, H.A. AlBinali, A.W. Al-Mulla, R. Singh, J. Al Suwaidi, Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation: insights from a 20-year registry in Qatar (1991-2010), Angiology 64 (2013) 498-504.
22. R. Mathur, E. Pollara, S. Hull, P. Schofield, M. Ashworth, J. Robson, Ethnicity and stroke risk in patients with atrial fibrillation, Heart 99 (2013) 1087-1092.
23. F. Valbusa, L. Bertolini, S. Bonapace, L. Zenari, G. Zoppini, G. Arcaro, C.D. Byrne, G. Targher, Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus, Am. J. Cardiol. 112 (2013) 499-504.
24. F. Valbusa, S. Bonapace, L. Bertolini, L. Zenari, G. Arcaro, G. Targher, Increased pulse pressure independently predicts incident atrial fibrillation in patients with type 2 diabetes, Diabetes Care 35 (2012) 2337-2339.
25. K. Negishi, S. Seicean, T. Negishi, T. Yingchoncharoen, W. Aljaroudi, T.H. Marwick, Relation of heart-rate recovery to new onset heart failure and atrial fibrillation in patients with diabetes mellitus and preserved ejection fraction, Am. J. Cardiol. 111 (2013) 748-753.
26. S. Boudina, E.D. Abel, Diabetic cardiomyopathy, causes and effects, Rev. Endocr. Metab. Disord. 11 (2010) 31-39.
27. S. Dublin, N.L. Glazer, N.L. Smith, B.M. Psaty, T. Lumley, K.L. Wiggins, et al., Diabetes mellitus, glycemic control, and risk of atrial fibrillation, J. Gen. Intern. Med. 25 (2010) 853-858.
28. R.K. Sandhu, D. Conen, U.B. Tedrow, K.C. Fitzgerald, A.D. Pradhan, P.M. Ridker, et al., Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation, J. Am. Heart Assoc. 3 (2014) e000916.
29. R. Pop-Busui, Cardiac autonomic neuropathy in diabetes: a clinical perspective, Diabetes Care 33 (2010) 434-441.
30. V. Urbancic-Rovan, B. Meglic, A. Stefanovska, A. Bernjak, K. Azman-Juvan, A. Kocijancic, Incipient cardiovascular autonomic imbalance revealed by wavelet analysis of heart rate variability in Type 2 diabetic patients, Diabet. Med. 24 (2007) 18-26.
31. H. Otake, H. Suzuki, T. Honda, Y. Maruyama, Influences of autonomic nervous systemon atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart, Int. Heart J. 50 (2009) 627-641.
32. K. Yano, T. Mitsuoka, T. Hirata, O. Hano, M. Hirata, Y. Matsumoto, Effect of bilateral stellectomy on electrical instability of the atrium in the dog with hypokalemia, Pacing Clin. Electrophysiol. 15 (1992) 314-323.
33. J. Heijman, N. Voigt, S. Nattel, D. Dobrev, Cellular andmolecular electrophysiology of atrial fibrillation initiation, maintenance, and progression, Circ. Res. 114 (2014) 1483-1499.
34. M. Watanabe, H. Yokoshiki, H. Mitsuyama, K. Mizukami, T. Ono, H. Tsutsui, Conduction and refractory disorders in the diabetic atrium, Am. J. Physiol. Heart Circ. Physiol. 303 (2012) H86-H95.
35. C. Liu, H. Fu, J. Li, W. Yang, L. Cheng, T. Liu, G. Li, Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits, Anadolu Kardiyol. Derg. 12 (2012) 543-550.
36. T. Kato, T. Yamashita, A. Sekiguchi, K. Sagara, M. Takamura, S. Takata, et al., What are arrhythmogenic substrates in diabetic rat atria? J. Cardiovasc. Electrophysiol. 17 (2006) 890-894.
37. T.F. Chao, K. Suenari, S.L. Chang, Y.J. Lin, L.W. Lo, Y.F. Hu, et al., Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose, Am. J. Cardiol. 106 (2010) 1615-1620.
38. H. Fu, C. Liu, J. Li, C. Zhou, L. Cheng, T. Liu, G. Li, Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits, Cardiol. J. 20 (2013) 59-67.
39. S. Ayhan, S. Ozturk, A. Alcelik, M.F. Ozlu, A. Erdem, T. Memioglu, et al., Atrial conduction time and atrialmechanical function in patients with impaired fasting glucose, J. Interv. Card. Electrophysiol. 35 (2012) 247-252.
40. G. Acar, A. Akcay, A. Sokmen, M. Ozkaya, E. Guler, G. Sokmen, et al., Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus, J. Am. Soc. Echocardiogr. 22 (2009) 732-738.
41. A. Akyel, F. Oksüz, M. Karadeniz, M. Yarlioʇlueş, G. Ergün, T. Cankurt, et al., Atrial electromechanical delay in type 2 diabetes mellitus, Wien. Klin. Wochenschr. 126 (2014) 101-105.
42. B. Burnstein, S. Nattel, Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation, J. Am. Coll. Cardiol. 51 (2008) 802-809.
43. T. Kato, T. Yamashita, A. Sekiguchi, T. Tsuneda, K. Sagara, M. Takamura, et al., AGEs- RAGE system mediates atrial structural remodeling in the diabetic rat, J. Cardiovasc. Electrophysiol. 19 (2008) 415-420.
44. J. Chen, Q. Li, R. Dong, H. Gao, H. Peng, Y. Wu, The effect of the Ras homolog gene family (Rho), member A/Rho associated coiled-coil forming protein kinase pathway in atrial fibrosis of type 2 diabetes in rats, Exp. Ther. Med. 8 (2014) 836-840.
45. K.K. Kadappu, A. Boyd, S. Eshoo, B. Haluska, A.E. Yeo, T.H. Marwick, L. Thomas, Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? Eur. Heart J. Cardiovasc. Imaging 13 (2012) 1016-1023.
46. P. Korantzopoulos, T.M. Kolettis, D. Galaris, J.A. Goudevenos, The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation, Int. J. Cardiol. 115 (2007) 135-143.
47. L. Rochette, M. Zeller, Y. Cottin, C. Vergely, Diabetes, oxidative stress and therapeutic strategies, Biochim. Biophys. Acta 2014 (1840) 2709-2729.
48. E.J. Anderson, A.P. Kypson, E. Rodriguez, C.A. Anderson, E.J. Lehr, P.D. Neufer, Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart, J. Am. Coll. Cardiol. 54 (2009) 1891-1898.
49. M. Mitasíková, H. Lin, T. Soukup, I. Imanaga, N. Tribulová, Diabetes and thyroid hormones affect connexin-43 and PKC-epsilon expression in rat heart atria, Physiol. Res. 58 (2009) 211-217.
50. T. Igarashi, J.E. Finet, A. Takeuchi, Y. Fujino, M. Strom, I.D. Greener, et al., Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation, Circulation 125 (2012) 216-225.
51. G. Lip, G. Varughese, Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links, Int. J. Cardiol. 105 (2005) 319-321.
52. P.E. Vardas, K. Vemmos, D.A. Sideris, Susceptibility of the right and left canine atria to fibrillation in hyperglycemia and hypoglycemia, J. Electrocardiol. 26 (1993) 147-153.
53. S. Saito, Y. Teshima, A. Fukui, H. Kondo, S. Nishio, M. Nakagawa, T. Saikawa, N. Takahashi, Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats, Cardiovasc. Res. 104 (2014) 5-14.
54. M. Odeh, A. Oliven, H. Bassan, Transient atrial fibrillation precipitated by hypoglycemia, Ann. Emerg. Med. 19 (1990) 565-567.
55. S. Celebi, O.O. Celebi, S. Aydogdu, E. Diker, A peculiar medical cardioversion of atrial fibrillation with glucose infusion-a rare cause of atrial fibrillation: hypoglycemia, Am. J. Emerg. Med. 29 (2011) 134.e1-134.e3.
56. J.D. Fontes, A. Lyass, J.M. Massaro, M. Rienstra, D. Dallmeier, R.B. Schnabel, et al., Insulin resistance and atrial fibrillation (from the Framingham Heart Study), Am. J. Cardiol. 109 (2012) 87-90.
57. S. Nattel, L.H. Opie, Controversies in atrial fibrillation, Lancet 367 (2006) 262-272.
58. D. Dobrev, S. Nattel, New antiarrhythmic drugs for treatment of atrial fibrillation, Lancet 375 (2010) 1212-1223.
59. D. Dobrev, S. Nattel, New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications, Cardiovasc. Res. 89 (2011) 689-691.
60. C. McGann, N. Akoum, A. Patel, E. Kholmovski, P. Revelo, K. Damal, et al., Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI, Circ. Arrhythm. Electrophysiol. 7 (2014) 23-30.
61. S.H. Chang, L.S. Wu, M.J. Chiou, J.R. Liu, K.H. Yu, C.F. Kuo, et al., Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies, Cardiovasc. Diabetol. 13 (2014) 123.
62. O. Fatemi, E. Yuriditsky, C. Tsioufis, D. Tsachris, T. Morgan, J. Basile, et al., Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study), Am. J. Cardiol. 114 (2014) 1217-1222.
63. I. Savelieva, N. Kakouros, A. Kourliouros, A.J. Camm, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for european society of cardiology guidelines. Part I: primary prevention, Europace 13 (2011) 308-328.
64. I. Savelieva, N. Kakouros, A. Kourliouros, A.J. Camm, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for european society of cardiology guidelines. Part II: secondary prevention, Europace 13 (2011) 610-625.
65. Y. Lin, H. Li, X. Lan, X. Chen, A. Zhang, Z. Li, Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus, Sci. World J. 2013 (2013) 209428.
66. A. Goette, U. Lendeckel, Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms, Europace 10 (2008) 238-241.
67. S. Cardin, D. Li, N. Thorin-Trescases, T.K. Leung, E. Thorin, S. Nattel, Evolutionof theatrial fibrillation substrate in experimental congestive heart failure:angiotensin-dependent and -independent pathways, Cardiovasc. Res. 60 (2003) 315-325.
68. J.M. Forbes, M.E. Cooper, V. Thallas, W.C. Burns, M.C. Thomas, G.C. Brammar, et al., Reduction of the accumulation of advanced glycation end products by ace inhibition in experimental diabetic nephropathy, Diabetes 51 (2002) 3274-3282.
69. T. Miyata, C. van Ypersele de Strihou, Y. Ueda, K. Ichimori, R. Inagi, H. Onogi, et al., Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms, J. Am. Soc. Nephrol. 13 (2002) 2478-2487.
70. C.I. Lee, J.Y. Guh, H.C. Chen, W.C. Hung, Y.L. Yang, L.Y. Chuang, Advanced glycation end-product-inducedmitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in nrk-49f cells, J. Cell. Biochem. 95 (2005) 281-292.
71. S. Yamagishi, M. Takeuchi, T. Matsui, K. Nakamura, T. Imaizumi, H. Inoue, Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through rage overexpression, FEBS Lett. 579 (2005) 4265-4270.
72. M. Fujita, H. Okuda, O. Tsukamoto, Y. Asano, Y.L. Hirata, J. Kim, et al., Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells, Arterioscler. Thromb. Vasc. Biol. 26 (2006) e138-e142.
73. T. Kato, T. Yamashita, A. Sekiguchi, T. Tsuneda, K. Sagara, M. Takamura, et al., Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling, J. Cardiol. 58 (2011) 131-136.
74. B. Cariou, B. Charbonnel, B. Staels, Thiazolidinediones and PPARλ agonists: time for a reassessment, Trends Endocrinol. Metab. 23 (2012) 205-215.
75. M. Shimano, Y. Tsuji, Y. Inden, K. Kitamura, T. Uchikawa, S. Harata, et al., Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure, Heart Rhythm. 5 (2008) 451-459.
76. O. Kume, N. Takahashi, O. Wakisaka, Y. Nagano-Torigoe, Y. Teshima, M. Nakagawa, et al., Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats, Heart Rhythm. 8 (2011) 278-285.
77. D. Xu, N. Murakoshi, M. Igarashi, A. Hirayama, Y. Ito, Y. Seo, et al., Ppar-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model, J. Cardiovasc. Electrophysiol. 23 (2012) 209-217.
78. T. Nakajima, K. Iwasawa, H. Oonuma, H. Imuta, H. Hazama, M. Asano, et al., Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes, Circulation 99 (1999) 2942-2950.
79. T. Liu, H. Zhao, J. Li, P. Korantzopoulos, G. Li, Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits, Cardiovasc. Ther. 32 (2014) 178-183.
80. Q. Zhang, T. Liu, C.Y. Ng, G. Li, Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies, Cardiovasc. Ther. 32 (2014) 233-241.
81. P. Korantzopoulos, S. Kokkoris, E. Kountouris, I. Protopsaltis, K. Siogas, A. Melidonis, Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy, Int. J. Cardiol. 125 (2008) e51-e53.
82. T.F. Chao, H.B. Leu, C.C. Huang, J.W. Chen, W.L. Chan, S.J. Lin, S.A. Chen, Thiazolidinediones can prevent new onset atrial fibrillation in patients with noninsulin dependent diabetes, Int. J. Cardiol. 156 (2012) 199-202.
83. J. Gu, X. Liu, X. Wang, H. Shi, H. Tan, L. Zhou, et al., Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus, Europace 13 (2011) 1256-1261.
84. T. Liu, G. Li, Thiazolidinediones as novel upstream therapy for atrial fibrillation in diabetic patients: a review of current evidence, Int. J. Cardiol. 156 (2012) 215-216.
85. T. Liu, G. Li, Probucol and succinobucol in atrial fibrillation: pros and cons, Int. J. Cardiol. 144 (2010) 295-296.
86. Y.T. Gong, W.M. Li, Y. Li, S.S. Yang, L. Sheng, N. Yang, et al., Probucol attenuates atrial autonomic remodeling in a caninemodel of atrial fibrillation produced by prolonged atrial pacing, Chin. Med. J. (Engl.) 122 (2009) 74-82.
87. Y. Li, L. Sheng, W. Li, W. Liu, Y. Gong, H. Xue, H. Shan, et al., Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs, Biochem. Biophys. Res. Commun. 381 (2009) 198-203.
88. H. Fu, G. Li, C. Liu, J. Li, X. Wang, L. Cheng, T. Liu, Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits, J. Cardiovasc. Electrophysiol. 26 (2) (2015) 211-222.
89. T. Liu, L. Li, P. Korantzopoulos, E. Liu, G. Li, Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies, Int. J. Cardiol. 126 (2008) 160-170.
90. T. Liu, P. Korantzopoulos, M. Shehata, G. Li, X. Wang, S. Kaul, Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials, Heart 97 (2011) 1034-1040.
91. T. Liu, P. Korantzopoulos, G. Li, Antioxidant therapies for the management of atrial fibrillation, Cardiovasc. Diagn. Ther. 2 (2012) 298-307.
92. A.A. Sovari, S.C. Dudley Jr., Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation, Front. Physiol. 3 (2012) 311.